MPMarcello Piacenti

Marcello Piacenti

*This is an algorithmically generated author record based on publicly available information.

Marcello Piacenti has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    P162 ARRHYTHMIC MITRAL VALVE PROLAPSE OCCURRING AS ABORTED SUDDEN CARDIAC DEATH

    by A Alberio, S Garibaldi, G Mirizzi, E Franchi, C Viacava, G Santoro, M Piacenti, A Rossi, N Assanta

    Mitral valve prolapse (MVP) is the common valvular heart disease, with a prevalence about 1–3% in the population. MVP is characterized on echocardiography by an abnormal systolic displacement of mitral valve leaflets into left atrium (LA) ≥ 2 mm above the mitral annulus. We described a clinical case of a 15 years–old boy with a first clinical presentation of out–of–hospital cardiac arrest related to ventricular fibrillation (VF) with a successful resuscitation after 2 DC shocks. Retrospectively, an episode of loss of awareness reported as post–minational. No familiar history of sudden cardiac death (SCD) or MVP was noticed. In the emergency room, the patient was hemodynamically unstable and was sedated and intubated. The surface electrocardiogram (ECG) showed sinus rhythm, QRS with fragmentation, and frequent monomorphic isolated premature ventricular contractions (PVCs) with RBBB/LAFB configuration.Frequent monomorphic PVCs with bigeminy was observed during continuous ECG monitoring, so the patient was treated with magnesium sulphate and metoprolol. The patient was subsequently weaned from ventilation support, presenting good gas exchange and without neurological sequalae. The 24h Holter monitoring showed an average of 53 bpm, extremely rare supraventricular extrasystoles, high incidence of monomorphic PVCs (23% of the total beats) with 4 couplets. Transthoracic echocardiography documented normal size and thickness with systolic function (GLS –21%, mild asynchrony of posterior basal segments), bi–leaflet prolapse associated to mild–moderate mitral regurgitation, and mitral annular disjunction (MAD) of 6.2 mm. The late gadolinium enhancement cardiac magnetic resonance showed bi–leaflet prolapse with mild insufficiency and maximum MAD 9 mm, mild LA dilatation, and slightly dilated both ventricles, without regional wall motion abnormalities; no scar or fibrosis at the late gadolinium enhancement was observed. According to guidelines, the patient received a subcutaneous implantable cardiac defibrillator for the secondary prevention of SCD and maintained under betablockers in order to control the arrhythmic burden. The genetic sampling did not show any pathogenetic mutation potentially related to cardiomyopathies or channelopathies. This case show an arrhythmic MVP complex with probably posterior papillary muscle source. The early PVCs with R/T constituted a possible trigger of VF. The betablocker therapy exhibited a full suppression of extrasystolic burden.

  • Open Access

    Prognostic value of right ventricular refractory period heterogeneity in Brugada syndrome. Independent predictor or part of something more complex? Author's reply

    by Andrea Rossi, Alberto Giannoni, Marcello Piacenti

    This is a response to the Letter to the Editor, ‘Prognostic value of right ventricular refractory period heterogeneity in Brugada syndrome. Independent predictor or part of something more complex?’ by Gregory Dendramis https://doi.org/10.1093/europace/euac248, about the article, ‘Prognostic value of right ventricular refractory period heterogeneity in Type-1 Brugada electrocardiographic pattern’ by Rossi et al. https://doi.org/10.1093/europace/euac168


  • Open Access

    Prognostic value of right ventricular refractory period heterogeneity in Type-1 Brugada electrocardiographic pattern

    by Andrea Rossi, Alberto Giannoni, Martina Nesti, Pasquale Notarstefano, Vincenzo Castiglione, Gianluca Solarino, Lucio Teresi, Gianluca Mirizzi, Vincenzo Russo, Luca Panchetti, et al.

    To investigate the prognostic significance of heterogeneity in the refractoriness of right ventricular (RV) outflow tract (RVOT) and RV apex at the electrophysiological study (EPS) in Brugada syndrome (BrS). A cohort of BrS patients (primary prevention) from five Italian centres was retrospectively analysed. Patients with spontaneous or drug-induced Type-1 electrocardiogram (ECG) + symptoms were offered an EPS for prognostic stratification. The primary endpoint was a composite of sudden cardiac death (SCD), resuscitated cardiac arrest, or appropriate intervention by the implantable cardioverter-defibrillator (ICD). Three hundred and seventy-two patients with BrS were evaluated (44 ± 15 years, 69% males, 23% with ICD): 4 SCDs and 17 ICD interventions occurred at follow-up (median 48, interquartile range: 36–60 months). Family history of SCD, syncope, and a spontaneous Type-1 ECG pattern were univariate predictors of the primary endpoint in the whole population. In patients undergoing EPS (n = 198, 53%, 44 ± 12 years, 71% males, 39% with ICD), 3 SCD and 15 ICD interventions occurred at follow-up. In this subset, the primary endpoint was not only predicted by ventricular tachycardia/fibrillation inducibility but also by a difference in the refractory period between RVOT and RV apex (ΔRPRVOT-apex) >60 ms. ΔRPRVOT-apex > 60 ms remained an independent predictor of SCD/ICD shock at bivariate analysis, even when adjusted for the other univariate predictors, showing the highest predictive power at C-statistic analysis (0.75, 95% confidence interval 0.63–0.86). Heterogeneity of RV refractory periods is a strong, independent predictor of life-threatening arrhythmias in BrS patients, beyond VT/VF inducibility at EPS and common clinical predictors. In patients with Type-1 ECG Brugada pattern, the presence of an increased difference in the refractoriness between the right ventricular outflow tract (RVOT) and the apex, mainly driven by an increased refractory period in the RVOT, increases the prognostic discrimination power of the electrophysiological study, currently based only on inducibility of life-threatening arrhythmias. BrS, Brugada syndrome; EPS, electrophysiological study; RP, refractory period; RV, right ventricle; RVOT, right ventricular outflow tract; VF, ventricular fibrillation; VT, ventricular tachycardia.